TECHNOLOGY SUMMARY

By providing immediate identification of all of the most common bacterial pathogens, QSM technology will change the management paradigm for treatment of infectious diseases with antibiotics. Our sensing approach utilizes proprietary aptamers developed against unique quorum sensing molecules (QSM) and virulence factors secreted by bacterial pathogens that identify the particular species that is present in infected bodily fluids. These target molecules are present in significantly greater quantities in specimens than the pathogenic cells, allowing immediate detection by our sensors. We have uniquely combined the selectivity and specificity provided by aptamers with an electrochemical sensing approach that allows quantitative measurement of the target molecule concentrations in any bodily fluid without sample preparation or external controls. Since aptamers can be generated for any biomarker, our electrochemical aptamer-based detection platform can be extended to other infections and diseases. The platform can also be integrated with medical devices to monitor chronically ill, at-risk patients for the presence of bacteria, prior to the start of symptoms associated with infection. Our timely diagnosis will allow directed treatment, reducing medical complications arising from infections and decreasing healthcare costs.

AREA/MATURITY/AWARDS

Primary Application Area: Medical Devices

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

Vetted Programs/Awards: NSF I-Corps Program, 2016 Mass Challenge Silver Award Winner, 2nd place in Pitch Competition at InnoShare International Conference July 2018 Poland

SHOWCASE SUMMARY

Organization Type: Early-stage Startup (Seed)

Showcase Booth #: 201

Website: https://qsmdiagnostics.com

GOVT/EXTERNAL FUNDING SOURCES

External Funding to Date: Bolt Ventures, NSF Phase 1 SBIR, Triple Ring Technologies, Northeastern Idea Gap Fund